Deposition of nebulized liposomal carriers within an upper airways replica

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216305%3A26210%2F22%3APU147047" target="_blank" >RIV/00216305:26210/22:PU147047 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Deposition of nebulized liposomal carriers within an upper airways replica
Original language description
Lung cancer is the most deadly cancer disease (18 % of deaths are caused by cancer) (Sung et al., 2021). Cancer treatment is connected with severe side effects due to whole-body exposure to strong cytotoxic anticancer drugs (Zhang et al., 2018). Inhalation treatment could decrease the exposure of the healthy organs and eliminate the side effects. Liposomal carrier systems are a perspective option of inhalation delivery of anticancer drugs, because of their biocompatibility, the longer retention in the lung, or targeted cellular therapy (Young et al., 2015). The liposome from 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) stabilized by cholesterol phosphatidic acid (PA) was nebulized by Pari LC Sprint Star nebulizer (Pari GmbH, Germany). MMAD (Mass Median Aerodynamic Diameter) of generated aerosol measured by Aerodynamic Particle Sizer (APS, TSI Inc., Minnesota) was 7.27±0.26 µm and GSD (Geometric Standard Deviation) was 1.54±0.01 µm. The deposition of a nebulized system in a replica of the huma
Czech name
—
Czech description
—

Project
<a href="/en/project/GA20-27653S" target="_blank" >GA20-27653S: Influence of infants and children lungs development on flow field and aerosol deposition– computational modelling and experimental validation</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)